Skip to main content
HALO logo

HALO · Halozyme Therapeutics, Inc. · Investor Relations

Track HALO — free
Market Cap
$10.57B
Shares
114.01M
Volume · Nov 19 750.48K Avg daily vol (3M) 2.24M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-06 Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
2026-11-06 U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
2026-11-05 HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
2026-10-22 Halozyme to Report Third Quarter 2026 Financial and Operating Results
2026-10-07 Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
2026-10-06 Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
2026-09-30 Halozyme Announces Appointment of Jim Daly to its Board of Directors
2026-09-18 Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
2026-09-16 Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
2026-09-02 Halozyme to Participate at Upcoming Investor Conferences
2026-08-18 Halozyme Appoints Dannielle Appelhans to its Board of Directors
2026-08-06 HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
2026-07-23 Halozyme to Report Second Quarter 2026 Financial and Operating Results
2026-07-20 Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
2026-06-30 Halozyme Appoints David Ramsay as President Drug Delivery
2026-06-15 Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
2026-05-11 HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
2026-05-07 Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
2026-05-06 Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
2026-04-30 Halozyme to Report First Quarter 2026 Financial and Operating Results
2026-04-30 Halozyme Appoints Darren Snellgrove as Chief Financial Officer
2026-04-07 Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
2026-03-12 Halozyme Appoints David Ramsay as Interim Chief Financial Officer
2026-03-06 U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
2026-02-25 Halozyme to Participate in Upcoming Investor Conferences

Past events

Date Event Type
2026-11-05 Halozyme Therapeutics, Inc. Q3 FY2026 Earnings Call Earnings call
2026-11-05 Halozyme 3Q 2026 Financial and Operating Results Event
2026-09-16 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-15 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-09 Wells Fargo 21st Annual Healthcare Conference Conference
2026-08-06 Halozyme 2Q 2026 Financial and Operating Results Event
2026-08-06 Halozyme Therapeutics, Inc. Q2 FY2026 Earnings Call Earnings call
2026-05-11 Q1 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-05-11 Halozyme 1Q 2026 Financial and Operating Results Event
2026-03-11 The Citizens Life Sciences Conference Conference
2026-03-10 Leerink Partners Global Healthcare Conference Conference
2026-03-03 TD Cowen 46th Annual Healthcare Conference Conference
2026-02-17 Halozyme 4Q and FY 2025 Financial and Operating Results Conference Call Earnings call
2026-01-28 Investor Conference Call Conference
2026-01-28 Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update Earnings call
2025-12-02 8th Annual Evercore Healthcare Conference Conference
2025-11-03 Halozyme Therapeutics, Inc. Q3 FY2025 Earnings Call Earnings call
2025-10-01 Halozyme Investor Call Event
2025-09-08 Morgan Stanley 23rd Annual Global Healthcare Conference Conference
2025-09-04 2025 Wells Fargo Healthcare Conference Conference
2025-08-05 Halozyme Therapeutics, Inc. Q2 FY2025 Earnings Call Earnings call
2025-06-09 Goldman Sachs 46th Annual Global Healthcare Conference Conference
2025-05-13 BofA Securities 2025 Healthcare Conference Conference
2025-05-06 Halozyme Therapeutics, Inc. Q1 FY2025 Earnings Call Earnings call
2025-03-05 TD Cowen 45th Annual Healthcare Conference Conference

Source: https://ir.halozyme.com/overview/default.aspx

Key facts CIK 1159036 CUSIP 40637H109 13F (30d) 736 filings 687 filers Visit website Investor relations